Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Biocon Biologics and Sandoz Sign Distribution Agreement for Adalimumab BS, Biosimilar to Amgen’s Humira® in Japan

Dec 22, 2023

Biocon Biologics announced it has signed a Distribution Agreement with Sandoz granting Sandoz the exclusive right to promote, sell and distribute “adalimumab BS for subcutaneous injection”, a biosimilar to Amgen’s Humira®, in Japan.

Biocon Biologics acquired the global biosimilars portfolio of Viatris with a deal signed in November 2022.  It completed integration in Europe in November 2023, and in North America in September 2023.  The most recent announcement states that Viatris will continue to provide transition support until Sandoz assumes responsibility for the product from 15 February 2024.